Download PDF
Allgemein- und Viszeralchirurgie up2date 2015; 9(03): 232-245
DOI: 10.1055/s-0041-100228
Viszerale Transplantationen
Georg Thieme Verlag KG Stuttgart · New York

Aktueller Stand der immunsuppressiven Therapie unter besonderer Berücksichtigung des transplantierten Patienten in der Chirurgie

U. Herden
,
B. Nashan
,
M. Koch
Further Information

Publication History

Publication Date:
19 June 2015 (online)

Also available at
    Permissions and Reprints All articles of this category

Corrected by:

Aktueller Stand der immunsuppressiven Therapie unter besonderer Berücksichtigung des transplantierten Patienten in der ChirurgieAllgemein- und Viszeralchirurgie up2date 2015; 9(04): 333-333
DOI: 10.1055/s-0035-1558072

Die Zahl organtransplantierter Patienten ist kontinuierlich steigend, sodass auch niedergelassene Ärzte und Ärzte in nicht transplantierenden Krankenhäusern und in Praxen zunehmend mit der Betreuung transplantierter Patienten konfrontiert werden.

 

  • Quellenangaben

  • 1 Hahn H, Falke D, Kaufmann S, Ullmann U. Medizinische Mikrobiologie und Infektiologie. 4. Aufl.. Berlin, Heidelberg, New York: Springer; 2000
    Google Scholar
  • 2 Herdegen T. Kurzlehrbuch Pharmakologie. Stuttgart: Thieme; 2008
    Google Scholar
  • 3 Pezzutto A, Ulrichs T, Burmester GR. Taschenatlas der Immunologie. 2.Aufl.. Stuttgart: Thieme; 2006
    Google Scholar
  • 4 Novartis Pharma Stein AG. Zortress (Everolimus) Highlights of prescribing Information. 2013 Im Internet: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021560s006lbl.pdf Stand: 23.03.2015
    Google Scholar
  • 5 Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002; 11: 1845-1857
    CrossrefGoogle Scholar
  • 6 Nashan B, Gaston R, Emery V et al. Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 2012; 93: 1075-1085
    CrossrefGoogle Scholar
  • 7 Novartis P. Fachinformation Certican (Everolimus). 2012.
    Google Scholar
  • 8 Trotter JF, Lizardo-Sanchez L. Everolimus in liver transplantation. Curr Opin Organ Transplant 2014; 19: 578-582
    CrossrefGoogle Scholar
  • 9 Azzola A, Havryk A, Chhajed P et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004; 77: 275-280
    CrossrefGoogle Scholar
  • 10 Nashan B, Citterio F. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. Transplantation 2012; 94: 547-561
    Google Scholar
  • 11 Nashan B. mTOR inhibitors and their role in modern concepts of immunosuppression. World J Surg 2014; 38: 3199-3201
    CrossrefGoogle Scholar
  • 12 Koch M, Kantas A, Ramcke K et al. Surgical complications after kidney transplantation: Different impacts of immunosuppression, graft function, patient variables, and surgical performance. Clin Transplant 2015; 29: 252-260
    CrossrefGoogle Scholar
  • 13 Schwarz L, Cauchy F, Conti F et al. Preliminary report of major surgery in liver transplant recipients receiving m-TOR inhibitors without therapeutic discontinuation. World J Surg 2014; 38: 3193-3198
    CrossrefGoogle Scholar
  • 14 U.S. Food and Drug Administration. Sandimmune (Cyclosporine, USP) Injection, Oral solution and Gelatin Capsules. 2013 Im Internet: http://www.fda.gov/safety/medwatch/safetyinformation/ucm319403.htm Stand: 23.03.2015
    Google Scholar
  • 15 Astellas Pharma US, Inc. Tacrolimus (Prograf). Highlights of prescribing information. 2011 Im Internet: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050708s036s037,050709s028s030lbl.pdf Stand: 23.03.2015
    Google Scholar
  • 16 Bundesministerium für Gesundheit. Richtlinie über die Verordnung von Arzneimitteln in der vertragsärztlichen Versorgung. Abschnitt M § 40 18.09.2014.
    Google Scholar
  • 17 Sgourakis G, Dedemadi G. Corticosteroid-free immunosuppression in liver transplantation: an evidence-based review. World J Gastroenterol 2014; 20: 10703-10714
    CrossrefGoogle Scholar
  • 18 Klintmalm GB, Feng S, Lake JR et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant 2014; 14: 1817-1827
    CrossrefGoogle Scholar
  • 19 De Simone P, Nevens F, De Carlis L et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012; 12: 3008-3020
    CrossrefPubMedGoogle Scholar
  • 20 Rote Liste Service GmbH (Herausgeber und Verlag). Rote Liste 2014 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte). 54. Ausgabe. Frankfurt/Main.
    Google Scholar
  • 21 AQUA – Institut für angewandte Qualitätsförderung und Forschung im Gesundheitswesen GmbH. Benchmark-Report 2012. Im Internet: http://www.sqg.de Stand: 31.03.2015
    Google Scholar
  • 22 Opelz G, Döhler B. Collaborative Transplant Study. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009; 87: 795-802
    CrossrefGoogle Scholar
  • 23 Nashan B, Curtis J, Ponticelli C et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78: 1332-1340
    CrossrefGoogle Scholar
  • 24 Vitko S, Margreiter R, Weimar W et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521-2530
    CrossrefGoogle Scholar
  • 25 Webster AC, Lee VW, Chapman JR et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234-1248
    CrossrefGoogle Scholar
  • 26 Prince O, Savic S, Dickenmann M et al. Risk factors for polyoma virus nephropathy. Nephrol Dial Transplant 2009; 24: 1024-1033
    Google Scholar
  • 27 Habicht A, Broker V, Blume C et al. Increase of infectious complications in ABO-incompatible kidney transplant recipients–a single centre experience. Nephrol Dial Transplant 2011; 26: 4124-4131
    CrossrefGoogle Scholar
  • 28 Oettl T, Halter J, Bachmann A et al. ABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies. Nephrol Dial Transplant 2009; 24: 298-303
    Google Scholar
  • 29 Cai J, Terasaki PI, Bloom DD et al. Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. Transplantation 2004; 78: 919-924
    CrossrefGoogle Scholar
  • 30 Knechtle SJ, Pascual J, Bloom DD et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am J Transplant 2009; 9: 1087-1098
    CrossrefGoogle Scholar
  • 31 Roodnat JI, Hilbrands LB, Hene RJ et al. 15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation. Transplantation 2014; 98: 47-53
    CrossrefGoogle Scholar
  • 32 Naesens M, Salvatierra O, Benfield M et al. Subclinical inflammation and chronic renal allograft injury in a randomized trial on steroid avoidance in pediatric kidney transplantation. Am J Transplant 2012; 12: 2730-2743
    CrossrefGoogle Scholar
  • 33 Sarwal MM, Ettenger RB, Dharnidharka V et al. Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter randomized trial with three-year follow-up. Am J Transplant 2012; 12: 2719-2729
    CrossrefGoogle Scholar
  • 34 Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89: 1-14
    CrossrefGoogle Scholar
  • 35 Vincenti F, Blancho G, Durrbach A et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010; 21: 1587-1596
    CrossrefGoogle Scholar
  • 36 Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781
    CrossrefGoogle Scholar
  • 37 Charpentier B, Medina Pestana JO, Del C Rial M et al. Long-term exposure to belatacept in recipients of extended criteria donor kidneys. Am J Transplant 2013; 13: 2884-2891
    CrossrefGoogle Scholar
  • 38 Rostaing L, Vincenti F, Grinyo J et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant 2013; 13: 2875-2883
    CrossrefPubMedGoogle Scholar